Patisiran sodium is a double-stranded small interfering RNA (siRNA) that selectively targets a specific sequence within the transthyretin (TTR) messenger RNA (mRNA). By doing so, it effectively blocks the hepatic synthesis of both mutant and wild-type TTR. Patisiran sodium has significant applications in the field of hereditary TTR amyloidosis research.